Monday, June 17, 2019

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

The largest U.S. drugmaker agreed to pay a hefty premium of 62% for Array, which sells the combination treatment Braftovi and Mektovi for melanoma. But those drugs appear poised to become part of a promising triple combination for advanced colorectal cancer.

from Moneycontrol http://bit.ly/2XnSnJr

No comments:

Post a Comment

  Finding symbol of isotops by proton and neutron